A Multicenter randomized open label study in patients with esophageal cancer refractory or intorlerant to combination therapy with fluoropyrimidine
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
May 1, 2016
End Date
April 30, 2021
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
May 1, 2016
End Date
April 30, 2021